跳至主要内容
临床试验/NCT02546414
NCT02546414已完成不适用

Platelet Count(PC)/Spleen Diameter(SD) Ratio to Predict the Variceal Haemorrhage in HBV Cirrhotic Patients in China

RenJi Hospital1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2013年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
150
试验地点
1
主要终点
Platelet count/spleen diameter ratio

研究概览

简要总结

To validate the PC/SD ratio to be used to predict the variceal haemorrhage in Chinese patients with hepatitis B virus (HBV)-associated hepatic cirrhosis.

详细描述

Esophageal variceal bleeding remains the leading cause of acute mortality in patients with cirrhosis. Using noninvasive parameters for high-risk variceal haemorrhage may reduce the need for endoscopies. The ratio of platelet count/diameter of the spleen (PC/SD ratio) is the principal noninvasive predictor of esophageal varices. This was an analytical cross-sectional study to validate the diagnostic test for HBV hepatic cirrhosis and was performed between January 2013 and August 2015. This study is to validate the PC/SD ratio to identification of those patients with high bleeding risk and selection for prophylactic treatment.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
45 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with a diagnosis of HBV hepatic cirrhosis

排除标准

  • Patients with hepatocellular carcinoma,
  • use of medications for the primary prophylaxis of variceal bleeding,
  • history of esophageal variceal bleeding,
  • alcohol consumption within the admission and a history of ligation,
  • sclerotherapy, and/or
  • portal hypertension surgery

结局指标

主要结局

Platelet count/spleen diameter ratio

时间窗: up to 2.5 years

This was an analytical cross-sectional study to validate the diagnostic test for HBV hepatic cirrhosis and was performed between January 2013 and August 2015

次要结局

  • Child-Pugh score.(up to 2.5 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shengliang Chen

MD

RenJi Hospital

研究点 (1)

Loading locations...

相似试验

Platelet Count(PC)/Spleen Diameter(SD) Ratio to... | 临床试验